Head-to-head evidence
LY03003 vs rotigotine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
LY03003
Developed by Luye Pharma Group
NCT04571164 · Phase 3 · completed
The trial randomized 294 participants to LY03003 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in the clinical UPDRS parts II+III score over 24 weeks, but the primary comparison and safety findings are not available, preventing assessment of whether the endpoint was met.
rotigotine · Neupro
Marketed by UCB
NCT00244387 · Phase 3 · completed
Although the registry reports a randomized, double-blind design with 506 participants, it lists no comparator arm, so the treatment cannot be evaluated against another treatment or placebo from the available record. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03003's landscape · rotigotine's landscape